Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 2, 2006, Pages 219-225

  Amirfar, Sam ^a   Hollenberg, James P ^a   Abdool Karim, Salim S ^a,b,c  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cost effectiveness; Decision analysis; HIV AIDS; Perinatal transmission; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENCE; ARTICLE; BREAST FEEDING; COHORT ANALYSIS; COMPUTER SIMULATION; DRUG COST; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; POLICY; PRIORITY JOURNAL; SOUTH AFRICA; VACCINATION; VERTICAL TRANSMISSION;

ADOLESCENT; AIDS VACCINES; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; SOUTH AFRICA;

EID: 33749019447     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000230526.79341.83     Document Type: Article

References (38)

1. UNAIDS. National response brief. Available at: http://www.unaids.org/ nationalresponse/result.asp. 7/8/2004.
2. Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, HIV Incidence, Behaviour and Communication Survey, 2005. Cape Town, South Africa: Human Sciences Research Council; 2005.
3. McLean AR, Blower SM, Auvert B, et al. Modelling HIV vaccination. Trends Microbiol. 1995;3:458-462.
4. Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr. 2002;29:132-141.
5. Anderson RM, Swinton J, Garnett GP, et al. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc R Soc Lond B Biol Sci. 1995;261:147-151.
6. Van Ballegooijen M, Bogaards JA, Weverling GJ, et al. AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination. J Acquir Immune Defic Syndr. 2003;34:214-220.
7. Owens DK, Edwards DM, Shachter RD. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics. AIDS. 1998;12:1057-1066.
8. Bishai D, Lin MK, Kiyonga CW. Modeling the economic benefits of an AIDS vaccine. Vaccine. 2001;20:526-531.
9. Pettifor AE, Rees HV, Steffenson A, et al. HIV and Sexual Behaviour Among Young South Africans: A National Survey of 15-24 Year Olds. Johannesburg, South Africa: Reproductive Health Research Unit, University of the Witwatersrand; 2004.
10. Schoub BD, Matai U, Singh B, et al. Universal immunization of infants with low doses of a low-cost, plasma-derived hepatitis B vaccine in South Africa. Bull World Health Organ. 2002;80:277-281.
11. Uzicanin A, Zhou F, Eggers R, et al. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa. Vaccine. 2004; 22:3419-3426.
12. Stover J, Garnett GP, Seitz S, et al. The Epidemiological Impact of an HIV/AIDS Vaccine in Developing Countries: Working Paper Number 2811. Washington, DC: European Commission and the Development Research Group of the World Bank; 2002.
13. Halloran ME, Haber M, Longini IM, Jr. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol. 1992;136:328-343.
14. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B Biol Sci. 1993;253:9-13.
15. Gouws E, Williams BG, Sheppard HW, et al. High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion. J Acquir Immune Defic Syndr. 2002;29:531-535.
16. Collaborative Group on AIDS Incubation and HIV Survival, Including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet. 2000;355:1131-1137.
17. Republic of South Africa Department of Health. National HIV and Syphilis Antenatal Sero-prevalence Survey in South Africa: 2002. South Africa: Republic of South Africa Department of Health; 2003.
18. Actuarial Society of South Africa, Cape Town, South Africa. ASSA AIDS and demographic models [database online]. Available at: http://www. assa.org.za/default.asp?id=1000000050.
19. Statistics South Africa Census 2001. 2001 South African census [database online]. Available at: http://www.statssa.gov.za/census01/census/dialog/ statfile.asp.
20. United Nations Population Fund. UNFPA state of world populations 2003: investing in adolescent's healths and rights [database online]. New York: United Nations Population Fund. Available at: http://www.unfpa.org/upload/ lib_pub_file/221_filename_swp2003_eng.pdf.
21. Sewankambo NK, Gray RH, Ahmad S, et al. Mortality associated with HIV infection in rural Rakai District, Uganda. AIDS. 2000;14:2391-2400.
22. Fawzi W, Msamanga G, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS. 2001; 15:1157-1165.
23. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet. 1999;354:795-802.
24. Morris AB, Cu-Uvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr. 2000;25:306-311.
25. Le Coeur S, Kanshana S, Jourdain G. HIV-1 transmission from mother to child and its prevention. Med Trop. 2003;63:381-390.
26. US Census Bureau. International database [database online]. Available at: http://www.census.gov/ipc/www/idbnew.html.
27. South African Department of Health. 1998 South Africa Demographic and Health Survey. Republic of South Africa; 1998.
28. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. BJOG. 1998;105:836-848.
29. Nakiyingi JS, Bracher M, Whitworth JA, et al. Child survival in relation to mother's HIV infection and survival: evidence from a Ugandan cohort study. AIDS. 2003;17:1827-1834.
30. Schim van der Loeff MF, Jaffar S, Aveika AA, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS. 2002;16:1775-1783.
31. Orrell C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369-1375.
32. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385-393.
33. Blecher M, Thomas S. Health care financing. In: Ijumba P, Day C, Ntuli A, eds. South African Health Review 2003/04. Durban, South Africa: Health Systems Trust; 2004. Available at: http://www.hst.org.za/publications/423.
34. Council for Medical Schemes. Annual Report of the Registrar of Medical Schemes 2003-4. Pretoria, South Africa: Council for Medical Schemes; 2004. Available at: http://www.medicalschemes.com.
35. Cleary S, Boulle A, McIntyre D, Coetzee D.Cost-Effectiveness of Antiretroviral Treatment for HIV-Positive Adults in a South African Township. Durban, South Africa: Health Systems Trust; 2004.
36. Geffen S, Nattrass N, Raubenheimer C. The Cost of HIV Prevention and Treatment Interventions in South Africa: Working Paper No. 28. Cape Town, South Africa: Centre for Social Science Research; 2003.
37. Skordis J, Nattrass N. Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa. J Health Econ. 2002;21:405-421.
38. Mbewu A.Operational Plan for Comprehensive HIV and AIDS Care, Management and Treatment for South Africa. South Africa: South African Department of Health; 2003.